Patient Information
Ebastina Viatris 20 mg Film-Coated Tablets
Read this leaflet carefully before you start taking this medicine because it contains important information for you.
Ebastina belongs to a group of medications called antihistamines.
Ebastina Viatris is indicated for the symptomatic treatment of allergic processes such as:
Warnings and precautions
Consult your doctor or pharmacist before starting to take Ebastina Viatris.
This medication should be used with caution:
Do not use this medication if you have an acute allergic emergency, as ebastina (active ingredient of this medication) takes 1 to 3 hours to take effect.
Children
Ebastina 20 mg tablets should not be administered to children under 12 years old.
Other medications and Ebastina Viatris
Inform your doctor or pharmacist that you are taking, have taken recently, or may need to take any other medication.
The following medications may interact with Ebastina; in these cases, it may be necessary to change the dose or discontinue treatment with one of them:
No interactions have been described between ebastina and theophylline, warfarin, cimetidine, diazepam, and alcohol.
Interference with diagnostic tests
Ebastina may interfere with the results of skin allergy tests, so it is recommended not to perform them until 5-7 days after discontinuing treatment.
Taking Ebastina Viatris with food and drinks
The tablets can be taken with or without food.
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, or think you may be pregnant, consult your doctor or pharmacist before using this medication.
Pregnancy
There is no experience in pregnant women, so it is recommended to consult a doctor before taking ebastina. The doctor will decide whether it is advisable to start treatment.
Breastfeeding
It is unknown whether the medication passes into breast milk, so it should not be used during breastfeeding.
Driving and operating machinery
In men, no effects have been observed on psychomotor function, or on the ability to drive or operate machinery, at the recommended therapeutic doses. However, given that drowsiness and dizziness are among the adverse effects, observe your response to the medication before driving or operating machinery.
Ebastina Viatris contains lactose
This medication contains lactose. If your doctor has told you that you have a certain sugar intolerance, consult with them before taking this medication.
Follow exactly the administration instructions for this medication as indicated by your doctor or pharmacist. In case of doubt, consult your doctor or pharmacist again.
Remember to take your medication.
Your doctor will indicate the duration of your treatment with ebastina.
Dosage:
Use in adults and children over 12 years: The recommended dose is 10 mg per day, although some patients may require a dose of 20 mg once a day.
Use in patients with severe liver disease: Do not exceed a dose of 10 mg of ebastina per day. In this case, it is recommended to use the 10 mg ebastina presentation.
Administration form:
This medication is for oral administration. The tablets can be taken with or without food, with the help of a glass of water.
If you estimate that the action of ebastina is too strong or too weak, inform your doctor or pharmacist.
If you take more Ebastina Viatris than you should:
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicological Information Service, phone 914 620 420 (indicating the medication and the amount ingested) or go to the nearest hospital. Bring the remaining tablets, the packaging, and the complete box so that the healthcare staff can identify the medication you have taken more easily. .
The treatment of intoxication by this medication consists of gastric lavage and administration of the appropriate medication.
If you forgot to take Ebastina Viatris:
Do not take a double dose to compensate for the missed doses. Take the missed dose when you remember and then follow your usual schedule. However, if there are only a few hours left before the next dose, do not take the missed dose and wait for the next dose at the scheduled time.
If you have any other doubts about the use of this medication, ask your doctor or pharmacist.
Like all medications, Ebastina can produce adverse effects, although not all people will experience them.
In clinical trials and post-marketing experience, the following adverse effects have been observed:
Very Common(may affect more than 1 in 10 people)
Common(may affect up to 1 in 10 people)
Rare(may affect up to 1 in 1,000 people)
Unknown Frequency(cannot be estimated from available data)
Reporting Adverse Effects
If you experienceany type ofadverse effect, consult your doctor or pharmacist, even if it is apossibleadverse effect not listed in this prospectus.You can also report them directly to the Spanish System for Pharmacovigilance of Medicines for Human Use: https://www.notificaram.es. By reporting adverse effects, you can contribute to providing more information on the safety of this medication.
Keep this medication out of the sight and reach of children.
No special storage conditions are required.
Do not use this medication after the expiration date that appears on the packaging after CAD. The expiration date is the last day of the month indicated.
Medications should not be disposed of through drains or in the trash. Dispose of the packaging and medications you no longer need at the SIGRE collection point of your usual pharmacy. Ask your pharmacist how to dispose of the packaging and medications you no longer need. This will help protect the environment.
Ebastina Viatris 20 mg Composition
-The active ingredient is ebastina. Each tablet contains 20 mg of ebastina.
-The other components (excipients) are: lactose monohydrate, microcrystalline cellulose (E460), pregelatinized cornstarch, povidone 30, polisorbate 80, magnesium stearate (E470B), hypromellose (E464), titanium dioxide (E171), and triacetin.
Product appearance and packaging contents
Ebastina Viatris is presented in the form of film-coated tablets, white in color. Each PVC/Aluminum blister contains 20 tablets.
Marketing Authorization Holder
Viatris Pharmaceuticals, S.L.U.
C/ General Aranaz, 86
28027 - Madrid
Spain
Responsible for manufacturing
Laboratorios ALTER, S.A.
C/ Mateo Inurria, 30
28036 – Madrid
Spain
Last review date of this leaflet:May 2025
The detailed information of this medicine is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS)https://www.aemps.gob.es/
Есть вопросы по этому лекарству или вашим симптомам? Свяжитесь с лицензированным врачом для получения помощи и персонализированного ухода.